A Phase 3 interventional study of Risankizumab in Plaque Psoriasis, sponsored by AbbVie. Completed at 57 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-27.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 3, and was the 18th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 19th largest by enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2019, is one of 31 in phase 3, and was the 61st registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms.
Study duration will last for up to 64 weeks with risankizumab given by subcutaneous injection at Week 0, Week 4, and then every 12 weeks for 52 Weeks (With the last dose being administered at Week 40). An additional visit will occur at Week 8 for a physical exam and questionnaire collection. A final follow-up phone call will occur at Week 60.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
Drug: Risankizumab
Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
Also known as: SKYRIZI
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: At Week 16
Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: At Week 16
Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.
Time frame: At Week 16
Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0
The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).
Time frame: At Week 16
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: At Week 52
Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: At Week 52
Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.
Time frame: At Week 52
Proportion of Participants Achieving a PSS 0
The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).
Time frame: At Week 52
Time to Achieve sPGA 0/1
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: Up to Week 52
Time to Achieve sPGA 0
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: Up to Week 52
Significant site non-compliance for this study was identified at one site since interim results were posted. As a result of this finding, participants enrolled in this trial site were not included in any final analysis. Adverse events or lab abnormalities were reported in 1 participant from this site. The participant was on risankizumab and had a non serious event of headache (assessed as mild), which did not lead to study drug discontinuation
| Milestone | Risankizumab |
|---|---|
| Started | 244 |
| Completed | 205 |
| Not completed | 39 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 12 |
| Withdrew: Eligibility violation | 5 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Protocol deviation | 5 |
| Withdrew: Protocol compliance | 1 |
| Withdrew: Withdrew treatment | 2 |
| Withdrew: Pregnancy | 1 |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 | 140 |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving a sPGA Clear Response (sPGA 0) | 50 |
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1 | 98 |
The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0 | 51 |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 | 152 |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving a sPGA Clear Response (sPGA 0) | 66 |
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1 | 115 |
The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).
| Participants | Risankizumab |
|---|---|
| Proportion of Participants Achieving a PSS 0 | 67 |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
| Days | Risankizumab |
|---|---|
| 25th | 30 (29 to 38) |
| Median | 57 (57 to 110) |
| 75th | 199 (134 to 282) |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
| Days | Risankizumab |
|---|---|
| 25th | 121 (113 to 201) |
| Median | 370 (366 to NA) |
| 75th | NA (NA to NA) |
Collected over From Baseline Day 1 up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risankizumab | 0/244 (0%) | 17/244 (7%) | 31/244 (12.7%) |
| Event | Risankizumab |
|---|---|
| MYOCARDIAL INFARCTIONCardiac disorders | 2/244 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 2/244 |
| CORONARY ARTERY DISEASECardiac disorders | 1/244 |
| LARGE INTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/244 |
| OEDEMATOUS PANCREATITISGastrointestinal disorders | 1/244 |
| OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders | 1/244 |
| CHOLELITHIASISHepatobiliary disorders | 1/244 |
| APPENDICITISInfections and infestations | 1/244 |
| DIVERTICULITISInfections and infestations | 1/244 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 1/244 |
| Event | Risankizumab |
|---|---|
| COVID-19Infections and infestations | 21/244 |
| NASOPHARYNGITISInfections and infestations | 14/244 |
| Age, Continuous(years) | Risankizumab |
|---|---|
| Mean | 49.2 ± 12.81 |
| Age, Customized(Participants) | Risankizumab |
|---|---|
| < 40 years | 65 |
| 40 - 65 years | 150 |
| ≥ 65 years | 29 |
| Sex: Female, Male(Participants) | Risankizumab |
|---|---|
| Female | 63 |
| Male | 181 |
| Ethnicity (NIH/OMB)(Participants) | Risankizumab |
|---|---|
| Hispanic or Latino | 17 |
| Not Hispanic or Latino | 227 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Risankizumab |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 27 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 214 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Risankizumab |
|---|---|
| United States | 64 |
| Germany | 65 |
| Italy | 27 |
| Spain | 17 |
| United Kingdom | 12 |
| Israel | 34 |
| Australia | 3 |
| Taiwan | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvieclinicaltrials.com
Ran from Nov 2019 to primary completion in Jan 2022, 26 months.
Results were first posted in Mar 2023, 1 year 2 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 26 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab